Replies to post #129494 on Biotech Values

[DewDiligence]

I think docs will see BG-12 as the more effective drug.

Undoubtedly true. However, Copaxone’s claim to fame has never been stellar efficacy, but rather its modest efficacy and longstanding safety profile. Moreover, it helps Copaxone a little that BG-12 was not shown to be statsig superior on the primary or secondary efficacy endpoints, and hence sales reps will be unable to legally promote BG-12 as superior.

All told, I do not expect the CONFIRM study to have much impact, if any, on Copaxone sales.